Predict your next investment

Corporation
SOFTWARE (NON-INTERNET/MOBILE) | Supply Chain & Logistics Software
accera.com.br

See what CB Insights has to offer

Partners & Customers

1

About Accera

Accera is a data analytics company.

Accera Headquarter Location

Av. Theodomiro Porto da Fonseca, 3101 Prédio 10, 5º andar

Sao Leopoldo, 93022,

Brazil

+55 (11) 3081 5300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Accera News

Accera Appoints Dr. Judith Walker as Chief Medical Officer

Sep 18, 2019

May 3, 2017 Accera, Inc ., an Inventages portfolio company, today announced the appointment of Judith Walker, M.D., F.R.C.P. Dr. Walker joins Accera from QuintilesIMS where she held the position of Vice President of Product Development, providing leadership for the global clinical development of drugs in the areas of neurology and pain. “Dr. Walker brings to Accera over 20 years of experience in the global biopharmaceutical industry,” said Accera’s president and CEO, Charles Stacey, M.D. “Her wealth of expertise in neurology drug development will be invaluable as we advance our metabolic approach to the treatment of Alzheimer’s disease into the final stage. Dr. Walker will lead the progression of our newly formulated lead compound in Alzheimer’s and help build out our pipeline of drugs in the CNS space.” Prior to QuintilesIMS, Dr. Walker served as Senior Director of Medical Affairs at Teva Neuroscience, a division of Teva Pharmaceuticals. Before Teva Neuroscience, Dr. Walker held leadership roles in global product and global clinical development in neurology at Serono International (Merck KGaA). Dr. Walker continues to serve on the boards of Great Lakes Neuroscience and the pharmaceutical advisory board of the non-profit Accelerated Cure Project. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Walker received her medical degree from the University of Montréal and completed her residency in neurology at the University of Western Ontario. “Accera has one of the few drugs in late-stage development for Alzheimer’s disease which addresses a differentiated and well-validated target,” said Dr. Walker. “I am delighted to be joining Accera at this exciting time in the program.” About Accera Accera, Inc. is a CNS therapeutics company based in Colorado, USA. The company’s proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer’s disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company’s management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera’s lead candidate is a small molecule drug compound in Phase 3 clinical development in patients with mild to moderate Alzheimer’s disease. For more information, visit www.accerapharma.com or follow Accera on Twitter at twitter.com/accerainc. recent news 2 months ago 11 months ago 2 years ago

Accera Acquisitions

3 Acquisitions

Accera acquired 3 companies. Their latest acquisition was Neogrid on October 25, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/25/2018

$99M

Merger

2

8/30/2017

Subscribe to see more

$99M

Subscribe to see more

10

8/24/2017

Seed / Angel

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/25/2018

8/30/2017

8/24/2017

Investment Stage

Seed / Angel

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

Note

Merger

Subscribe to see more

Subscribe to see more

Sources

2

10

10

Accera Partners & Customers

1 Partners and customers

Accera has 1 strategic partners and customers. Accera recently partnered with DuChemBio on July 7, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

7/11/2017

Partner

DuChemBio

South Korea

Accera Enters into a Strategic Partnership and Exclusive Licensing Agreement with DuChemBio for Accera's Technology in Korea

Ltd announced today that the companies have entered into a strategic partnership and exclusive licensing agreement whereby DuChemBio will obtain rights to develop , obtain regulatory approval and commercialize products in South Korea using Accera , Inc. 's medium chain triglyceride technology .

1

Date

7/11/2017

Type

Partner

Business Partner

DuChemBio

Country

South Korea

News Snippet

Accera Enters into a Strategic Partnership and Exclusive Licensing Agreement with DuChemBio for Accera's Technology in Korea

Ltd announced today that the companies have entered into a strategic partnership and exclusive licensing agreement whereby DuChemBio will obtain rights to develop , obtain regulatory approval and commercialize products in South Korea using Accera , Inc. 's medium chain triglyceride technology .

Sources

1

Accera Team

2 Team Members

Accera has 2 team members, including current Chief Financial Officer, Thiago Grechi.

Name

Work History

Title

Status

Thiago Grechi

Chief Financial Officer

Current

Cristhiano Fae

Chief Executive Officer

Former

Name

Thiago Grechi

Cristhiano Fae

Work History

Title

Chief Financial Officer

Chief Executive Officer

Status

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.